Nektar Therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. Nektar also partners with the top biopharmaceutical companies to bring new products to market. To date, Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.

Nov 17, 2015 Nektar Therapeutics to Present at Jefferies Autumn 2015 Global Healthcare Conference in London »
Nov 16, 2015 Baxalta to Advance Care for Hemophilia A patients with FDA Approval of ADYNOVATE, a Simple, Twice-weekly Treatment to Reduce Bleeds »
Nov 5, 2015 Nektar Therapeutics Reports Financial Results for the Third Quarter of 2015 »
Oct 29, 2015 Nektar to Announce Financial Results for the Third Quarter 2015 on Thursday, November 5, 2015, After Close of U.S.-Based Financial Markets »
Contact Nektar Investor Relations
Jennifer Ruddock
Vice President of Investor Relations and Corporate Affairs

Jodi Sievers
Associate Director, Investor & Corporate Communications

Transfer Agent and Stockholder Services
Computershare Shareholder Services
P.O. Box 43006
Providence, RI 02940-3006
Site Map Privacy Terms of Use Trademarks Site Users Guide